Cipla Q4 Results 2026: Profit Slumps 55% Despite Strong India Business
“The quarter was impacted by the absence of gRevlimid and lower Lanreotide contribution in North America,” Cipla’s management said on Wednesday, as the Mumbai-based drugmaker reported one of its weakest
